Maintaining bone health in prostate cancer throughout the disease continuum Review uri icon

Overview

MeSH Major

  • Androgen Antagonists
  • Bone and Bones
  • Diphosphonates
  • Imidazoles
  • Prostatic Neoplasms

abstract

  • Prostate cancer (PC) is the most prevalent malignancy in men, with 604,506 new cases diagnosed yearly worldwide. Maintaining bone health is important during all stages of PC, including patients who experience bone loss from androgen-deprivation therapy and patients who develop bone metastases. Patients with bone metastases often experience severe bone pain and are at increased risk for potentially debilitating skeletal-related events. Bisphosphonates are a well-established treatment option for patients with bone metastases from solid tumors and bone lesions from multiple myeloma. Zoledronic acid (ZOL) is the only bisphosphonate (BP) that has been extensively studied in patients with castration-recurrent PC and is indicated for treating patients with bone metastases from PC in conjunction with standard antineoplastic therapy. This review will examine the breadth of evidence supporting a role for ZOL and emerging therapies in managing patients with PC throughout the disease continuum.

publication date

  • June 2010

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1053/j.seminoncol.2010.06.007

PubMed ID

  • 20682370

Additional Document Info

start page

  • S30

end page

  • 7

volume

  • 37

number

  • SUPPL.